AU2018230737B2 - Tyk2 inhibitors, uses, and methods for production thereof - Google Patents

Tyk2 inhibitors, uses, and methods for production thereof Download PDF

Info

Publication number
AU2018230737B2
AU2018230737B2 AU2018230737A AU2018230737A AU2018230737B2 AU 2018230737 B2 AU2018230737 B2 AU 2018230737B2 AU 2018230737 A AU2018230737 A AU 2018230737A AU 2018230737 A AU2018230737 A AU 2018230737A AU 2018230737 B2 AU2018230737 B2 AU 2018230737B2
Authority
AU
Australia
Prior art keywords
compound
disorder
compounds
disease
tyk2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018230737A
Other languages
English (en)
Other versions
AU2018230737A1 (en
Inventor
Jean-Baptiste ARLIN
Jeremy Robert Greenwood
Jon P. Lawson
Jonathan James LOUGHREY
Craig E. Masse
David Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2018230737A1 publication Critical patent/AU2018230737A1/en
Application granted granted Critical
Publication of AU2018230737B2 publication Critical patent/AU2018230737B2/en
Priority to AU2022256121A priority Critical patent/AU2022256121A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: NIMBUS LAKSHMI, INC.
Priority to AU2024205575A priority patent/AU2024205575A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018230737A 2017-03-08 2018-03-07 Tyk2 inhibitors, uses, and methods for production thereof Active AU2018230737B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022256121A AU2022256121A1 (en) 2017-03-08 2022-10-19 Tyk2 inhibitors, uses, and methods for production thereof
AU2024205575A AU2024205575A1 (en) 2017-03-08 2024-08-07 Tyk2 inhibitors, uses, and methods for production thereof.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762468688P 2017-03-08 2017-03-08
US62/468,688 2017-03-08
PCT/US2018/021265 WO2018165240A1 (en) 2017-03-08 2018-03-07 Tyk2 inhibitors, uses, and methods for production thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022256121A Division AU2022256121A1 (en) 2017-03-08 2022-10-19 Tyk2 inhibitors, uses, and methods for production thereof

Publications (2)

Publication Number Publication Date
AU2018230737A1 AU2018230737A1 (en) 2019-09-19
AU2018230737B2 true AU2018230737B2 (en) 2022-09-22

Family

ID=63446346

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018230737A Active AU2018230737B2 (en) 2017-03-08 2018-03-07 Tyk2 inhibitors, uses, and methods for production thereof
AU2022256121A Abandoned AU2022256121A1 (en) 2017-03-08 2022-10-19 Tyk2 inhibitors, uses, and methods for production thereof
AU2024205575A Pending AU2024205575A1 (en) 2017-03-08 2024-08-07 Tyk2 inhibitors, uses, and methods for production thereof.

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022256121A Abandoned AU2022256121A1 (en) 2017-03-08 2022-10-19 Tyk2 inhibitors, uses, and methods for production thereof
AU2024205575A Pending AU2024205575A1 (en) 2017-03-08 2024-08-07 Tyk2 inhibitors, uses, and methods for production thereof.

Country Status (10)

Country Link
US (2) US10336752B2 (enExample)
EP (2) EP4338802A3 (enExample)
JP (3) JP7160824B2 (enExample)
CN (1) CN110582501B (enExample)
AR (1) AR111233A1 (enExample)
AU (3) AU2018230737B2 (enExample)
CA (1) CA3055209A1 (enExample)
IL (1) IL269036B2 (enExample)
TW (3) TWI783978B (enExample)
WO (1) WO2018165240A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788655B (zh) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
DK3658557T3 (da) 2017-07-28 2024-07-29 Takeda Pharmaceuticals Co Tyk2-inhibitorer og anvendelser deraf
UY38144A (es) 2018-03-12 2019-10-31 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa
CN113271940A (zh) 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
FI3870579T3 (fi) * 2018-10-22 2025-01-02 Alumis Inc Tyk2-inhibiittoreita ja niiden käyttöjä
AU2020218267A1 (en) * 2019-02-07 2021-09-30 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
BR112021019070A2 (pt) 2019-03-26 2022-02-15 Ventyx Biosciences Inc Ligantes de pseudoquinase tyk2
US11357775B2 (en) 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
IL287665A (en) * 2019-04-30 2022-07-01 Celgene Corp Combined treatments including apremilaste and tyk2 inhibitors
IL292785B2 (en) 2019-11-08 2025-09-01 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
EP4404930A1 (en) * 2021-09-23 2024-07-31 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
AU2022378463A1 (en) 2021-10-25 2024-05-09 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2023183910A1 (en) * 2022-03-25 2023-09-28 Nimbus Lakshmi, Inc. Solid forms of tyk2 inhibitors and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015131080A1 (en) * 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4983612A (en) * 1989-10-05 1991-01-08 American Home Products Corporation Antihypertensive benzopyran derivatives
DE4343923A1 (de) * 1993-12-22 1995-06-29 Basf Ag Pyridin-2,3-dicarbonsäureimide, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
CN1195755C (zh) 1999-12-10 2005-04-06 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DE60325740D1 (de) 2002-08-14 2009-02-26 Silence Therapeutics Ag Verwendung von protein-kinase-n-beta
WO2004046103A2 (en) * 2002-11-18 2004-06-03 The Regents Of The University Of California Arylpyridine compounds
JP2006523237A (ja) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
SI1644363T1 (sl) 2003-05-30 2012-07-31 Gemin X Pharmaceuticals Canada Inc Triheterociklične spojine sestavki in postopki za zdravljenje raka
EP2371835A1 (en) 2003-07-03 2011-10-05 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
ES2873875T3 (es) 2004-05-13 2021-11-04 Icos Corp Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano
NZ555947A (en) 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CN101282948A (zh) 2005-10-07 2008-10-08 埃克塞里艾克西斯公司 N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
DK2529622T3 (en) 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
RU2620376C2 (ru) * 2010-12-22 2017-05-25 Людвиг-Максимилианс-Университэт Мюнхен Цинкорганические комплексы, способы их получения и применение
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
PL2634185T3 (pl) * 2012-03-02 2016-06-30 Sareum Ltd Inhibitory kinazy TYK2
EP2855451B1 (en) 2012-05-24 2017-10-04 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
TWI620737B (zh) 2012-11-08 2018-04-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
WO2014074661A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES
WO2015089143A1 (en) 2013-12-10 2015-06-18 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
TWI788655B (zh) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
TWI825663B (zh) 2016-10-14 2023-12-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015131080A1 (en) * 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Brittain, H.G. in "Polymorphism in Pharmaceutical Solids", (1999), Marcel Dekker, Inc., New York, Edited by Brittain. *

Also Published As

Publication number Publication date
EP3592746A4 (en) 2020-11-25
TWI783978B (zh) 2022-11-21
TW202321243A (zh) 2023-06-01
CN110582501A (zh) 2019-12-17
AU2018230737A1 (en) 2019-09-19
US10336752B2 (en) 2019-07-02
CA3055209A1 (en) 2018-09-13
WO2018165240A1 (en) 2018-09-13
EP4338802A2 (en) 2024-03-20
IL269036A (en) 2019-10-31
JP2022185139A (ja) 2022-12-13
IL269036B (en) 2022-11-01
JP7535086B2 (ja) 2024-08-15
EP3592746B1 (en) 2024-01-24
EP3592746A1 (en) 2020-01-15
AU2024205575A1 (en) 2024-08-22
JP2024153877A (ja) 2024-10-29
IL269036B2 (en) 2023-03-01
US20180258086A1 (en) 2018-09-13
US20190337941A1 (en) 2019-11-07
AR111233A1 (es) 2019-06-19
TW202515876A (zh) 2025-04-16
JP7160824B2 (ja) 2022-10-25
TWI868528B (zh) 2025-01-01
AU2022256121A1 (en) 2022-11-17
JP2020511438A (ja) 2020-04-16
CN110582501B (zh) 2022-09-23
TW201840559A (zh) 2018-11-16
US11040967B2 (en) 2021-06-22
EP4338802A3 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
JP7535086B2 (ja) Ｔｙｋ２阻害剤、使用およびその製造のための方法
US10968236B2 (en) TYK2 inhibitors and uses thereof
US9790234B2 (en) IRAK inhibitors and uses thereof
US12338242B2 (en) TYK2 inhibitors and uses thereof
JP2025510844A (ja) Ｔｙｋ２阻害剤の合成及びその中間体
HK40017086B (en) Tyk2 inhibitors, uses, and methods for production thereof
HK40017086A (en) Tyk2 inhibitors, uses, and methods for production thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): NIMBUS LAKSHMI, INC.